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Background: It has been suggested that asthmatic subjects with persisting symptoms despite adequate
maintenance therapy should be systematically evaluated to identify factors contributing to poor control.
The aims of this study were to examine the prevalence of these factors in a cohort of sequentially
referred poorly controlled asthmatics, and to determine if any factor or combination of factors predicted
true therapy resistant asthma (TRA).
Methods: Patients were evaluated using a systematic evaluation protocol including induced sputum
analysis, psychiatric assessment, ear, nose and throat examination, pulmonary function testing, high
resolution CT scan of the thorax, and 24 hour dual probe ambulatory oesophageal pH monitoring; any
identified provoking factor was treated. Asthma was managed according to BTS guidelines.
Results: Of 73 subjects who completed the assessment, 39 responded to intervention and 34 had TRA.
Subjects with TRA had a greater period of instability, a higher dose of inhaled steroids at referral, more
rescue steroid use, and a lower best percentage forced expiratory volume in 1 second (FEV1%).
Oesophageal reflux, upper airway disease, and psychiatric morbidity were common (57%, 95%,
49%, respectively) but were not more prevalent in either group. Using multivariate logistic regression
analysis, inhaled steroid dose >2000 µg BDP, previous assessment by a respiratory specialist, and ini-
tial FEV1% of <70% at referral predicted a final diagnosis of TRA.
Conclusions: In poorly controlled asthmatics there is a high prevalence of co-morbidity, identified by
detailed systematic assessment, but no difference in prevalence between those who respond to
intervention and those with TRA. Targeted treatment of identified co-morbidities has minimal impact on
asthma related quality of life in those with therapy resistant disease.
National and international guidelines on the treatmentof asthma advocate a stepwise approach,1 2 and mostpatients respond to treatment with moderate doses of
inhaled corticosteroids alone or in addition to a long acting β2
agonist. Approximately 5% of adult patients remain difficult to
control despite high dose inhaled steroids, with persisting
breakthrough symptoms and frequent exacerbations requir-
ing systemic steroids.3 Debate exists as to the next best thera-
peutic intervention,1 but these patients are a cause of concern
because of persistent symptoms and impairment of quality of
life, continued impaired lung function, increased risk of
asthma death, and adverse effects of high dose
corticosteroids.3 4
It is likely that a number of factors contribute to lack of
adequate control in these subjects, including incorrect
diagnosis, unrecognised systemic disease, unrecognised trig-
ger factors (such as occupational exposures or gastro-
oesophageal reflux), poor compliance with treatment, and
psychosocial problems.3–5 Although these factors have been
proposed as contributing to poor asthma control in this popu-
lation, there has been little formal documentation regarding
their frequency and how targeted intervention affects
outcome. Indeed, the precise relationship between symptoms,
lung function, health related quality of life, and therapeutic
intervention remains to be established in this group.
The ERS Task Force on Difficult Asthma identified the need
for an “integrated approach to define clinical phenotypes,
evaluate risk factors, understand pathophysiology and find
novel therapies”.4 They also suggested a period of assessment
and evaluation to detect and,where possible, to modify factors
leading to poor control and subsequently to identify subjects
with definite therapy resistant asthma (TRA).
We hypothesised that subjects with poorly controlled
asthma who had identifiable provoking factors would respond
to targeted treatment of these factors and their asthma would
stabilise on reduced maintenance therapy. The aim of this
study was therefore to evaluate a cohort of sequentially
referred poorly controlled asthmatics using a systematic
evaluation protocol, and to identify factors contributing to
poor control, the frequency with which they occur, and to
determine if any factor or combination of factors predicted
true TRA.
METHODS
Patients were recruited for protocol evaluation if they had (1)
persisting refractory symptoms prompting referral to a
specialist, (2) minimal maintenance therapy of long acting β2
agonist and inhaled steroids (>800 µg beclomethasone dipro-
pionate (BDP) or equivalent), and (3) at least one course of
systemic steroids in the preceding 12 months.
Asthma was defined on the basis of typical symptoms
together with current or recently documented reversibility in
forced expiratory volume in 1 second (FEV1) of >12%.
6 All
recent admissions for asthma were reviewed to determine if
there was objective evidence of acute severe asthma at the
time of admission.
Patients were recruited to the protocol in a sequential unse-
lectedmanner. Those found at visit 1 not to fulfil the definition
of uncontrolled asthma outlined above were excluded at that
stage. All patients were seen and assessed by the same respi-
ratory physician at visit 1 and every subsequent clinical visit.
The protocol was run on an outpatient basis and coordinated
by an asthma nurse specialist.
Visit 1
At the initial visit a detailed semi-structured clinical history
was recorded for all subjects and a full physical examination
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was performed. Precipitants (oesophageal reflux, upper
airway disease, social difficulties, and psychiatric symptoms)
were graded by the assessing physician on the basis of clinical
history and graded 0 (not present/no symptoms), 1 (minor
factor/minor symptoms), or 2 (major factor/severe symp-
toms).
Skin prick testing to 12 inhalant allergens, chest radio-
graphy, spirometric testing with reversibility to nebulised β2
agonist, urinalysis, a standardised battery of blood tests, and
induced sputum (Medix Sonix ultrasonic nebuliser, 3% hyper-
tonic saline) were all performed, and an asthma related qual-
ity of life questionnaire7 and the Hospital Anxiety Question-
naire (HAD)8 were completed at visit 1.
The following investigations were arranged as part of the
investigative protocol: formal psychiatric interview, ear, nose
and throat examination, pulmonary function testing
(inspiratory/expiratory flow-volume loop, carbon monoxide
transfer factor and lung volumes by helium dilution), high
resolution CT scan of the thorax, 24 hour dual probe ambula-
tory oesophageal pH monitoring, and dual emission x ray
absorptiometry (DEXA). All subjects were offered the services
of a social worker if an underlying contributory social issue
was identified.
Inhaler technique was reviewed and patients were provided
with the device they found most suitable and could use prop-
erly (including the provision of combination inhalers). All
patients were provided with a written self-management plan,
and they were given advice on the roles of precipitants in pro-
voking their asthma symptoms and the precise role of differ-
ent inhaler medications in an attempt to maximise compli-
ance. They were instructed in keeping a peak flow record and
provided with a diary. Atopic patients were provided with a
standardised allergen avoidance sheet.
At visit 1 an initial management plan was instituted on
clinical grounds including the requirement for a course of sys-
temic steroids or the addition or reduction in therapy. All
reviews were determined by clinical need and patients were
asked to contact the clinic if their asthma deteriorated or if
they had an unscheduled asthma visit or hospital admission
and the details were recorded. At each review, clinical assess-
ment was performed and spirometric parameters recorded.
Management
Asthma was managed according to BTS guidelines with treat-
ment being stepped up and down as appropriate.1 The lowest
dose of inhaled corticosteroid required to control asthma
symptoms during the period of evaluation was recorded for
each subject. All patients were followed up for a minimum
period of 12 months after protocol assessment. If asthma
symptoms were controlled, subjects were classified as having
non-TRA andwere discharged. TRAwas defined in accordance
with the ERS Task Force on Difficult Asthma as persisting
symptoms due to asthma despite high dose inhaled steroids
(2000 µg beclomethasone, 1600 µg budesonide, 1000 µg fluti-
casone) plus a long acting β2 agonist with the requirement for
either maintenance systemic steroids or at least two rescue
courses of steroids in a follow up period of 12 months and
despite trials of other add-on therapies e.g. leukotriene recep-
tor antagonist or theophylline. An asthma related quality of
life questionnaire and the HAD questionnaire were completed
on discharge by subjects with non-TRA and 12–18 months
after protocol assessment by those with TRA.
If a subject failed to attend any follow up clinic
appointment a further appointment letter was sent and
telephone contact was made to identify the reason for
non-attendance, to establish if the patient’s asthma remained
stable, and to reinforce attendance at the new appointment. If
the subject failed to attend for three sequential appointments
no further appointments were made and the general
practitioner was informed. Telephone follow up to both the
subject and the primary care provider was made after 12–18
months in subjects lost to follow up to determine the outcome.
When investigations or assessments suggested a course of
treatment or action, this was arranged/prescribed at the time
of the investigation or at the next clinical review.
Co-existent diagnoses such as bronchiectasis or unrecog-
nised systemic disease were managed using standard inter-
ventions and treatments. If an external provoking factor was
identified—for example, occupational exposure/domestic
allergen—subjects were encouraged to take steps to exclude
the provoking factor and the success or failure to do so was
recorded. If patients gave a history of asthma symptoms con-
sistently related to particular foods or drinks, dietetic
assessment was arranged and, where appropriate, a trial
period of a relevant exclusion diet (for example, sulphites,
azo-dyes) instituted. If patients had an abnormal 24 hour
oesophageal pH profile (defined in our laboratory as a distal
oesophageal pH of <4 for more than 4.7% of total time9), a
standard treatment dose of proton pump inhibitor was
prescribed.
In patients with symptoms of rhinitis (itch, sneeze, rhinor-
rhoea, nasal obstruction) or evidence on ENT examination of
reactive nasal mucosa, mucus lying in the nose/post-nasal
space, a standard dose of nasal steroid ± oral antihistamine
was instituted. Other ENT diagnoses such as nasal polyps, sig-
nificant inferior nasal turbinate hypertrophy, or sinusitis were
treated using standard medical treatment and, if this failed, a
CT scan of the sinuses was performed and surgical options
considered.
Psychiatric diagnoses and treatment were determined by
the psychiatrist at the time of assessment and an individual
agreed treatment programme designed, involving pharmaco-
therapy and referral to a community psychiatric nurse, social
worker, and clinical psychologist.
Dysfunctional breathlessness (atypical symptoms and exer-
tional limitation inconsistent with pulmonary function) was
managed with explanation and referral to a specialist physio-
therapist for control of breathlessness/stress management and
a graded exercise programme plus any additional intervention
recommended after psychiatric assessment. If this did not
result in a clinical response, cardiopulmonary exercise testing
was arranged to quantify exercise capacity and provide
physiological evidence to support a diagnosis of dysfunctional
breathlessness.
Vocal cord dysfunction (VCD) was diagnosed on the basis of
inspiratory stridor when symptomatic plus a combination of
two of the following: abnormal inspiratory limb of the
flow-volume loop, previous intubation with normal inflation
pressures, or abnormal inspiratory cord motion on direct visu-
alisation. VCD was managed with explanation and a speech
and language therapy programme for control of
breathlessness/voice control plus any additional intervention
recommended after psychiatric assessment.
Severe chronic obstructive pulmonary disease due to
chronic asthma (post-bronchodilator FEV1 <40% predicted)
was managed with an explanation of the mechanism of
breathlessness, optimisation of bronchodilator therapy and,
where clinically indicated, referral to a pulmonary rehabilita-
tion programme.
Chronic bronchitis was diagnosed with a history of daily
cough and sputum production in the presence of stable
asthma, normal high resolution CT scan of the thorax, and
clinical and bacteriological evidence of recurrent bacterial
infection.
Statistical analysis
Demographic data are presented as mean (SE) or as absolute
values. Univariate analysis was performed using the unpaired
t test for continuous variables and χ2 analysis for dichotomous
variables and, where appropriate, χ2 for trend. Logistic
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regression analysis was subsequently performed to identify
the independent variables which best predicted TRA. All
statistics were performed using SPSS for Windows version 11.
RESULTS
Over an 18 month recruitment period 86 patients were
referred, six of whom were omitted at visit 1 because they did
not fulfil the entry criteria at the time of first attendance (four
were not taking a long acting β2 agonist despite its apparent
prescription and two were no longer difficult to control).
Of the remaining 80 subjects, six were lost to analysis (four
were non-compliant with the protocol, one had oesophageal
adenocarcinoma diagnosed during evaluation, and one
emigrated). Telephone follow up of the four subjects who were
non-compliant with the protocol indicated that one with a
provisional diagnosis of VCD/hyperventilation had stopped all
asthma treatment and remained well, and one with dysfunc-
tional breathlessness had stopped inhaled steroid therapy but
still used relief short acting β2 agonist. The other two subjects
(one with a prominent phobia of hospital and one with very
poor compliance) followed a pattern of recurrent exacerbation
and systemic steroid use managed in primary care. In one fur-
ther subject a diagnosis of asthma could not be sustained after
review of attendance and serial lung function. Of the remain-
ing 73 subjects, 34 were classified as having TRA after evalua-
tion. The demographic details of these subjects are shown in
table 1.
During evaluation eight subjects (11%) did not have a psy-
chiatric assessment (five refused assessment, one lost referral,
one already attending clinical psychology, and one failed to
Table 1 Demographic details at referral of all subjects and those classified as therapy resistant asthma (TRA) and
non-TRA after evaluation
All patients (n=73) TRA (n=34) Non-TRA (n=39) p value
Age (years) 42.6 (1.8) 43.2 (2.2) 42.0 (2.8) NS
Female (%) 49 (67%) 21 (62%) 28 (72%) NS
Age of asthma diagnosis (years) 22.0 (2.1) 19.9 (3.0) 23.9 (3.0) NS
Period of instability (months) 53.9 (8.0) 75.1 (14.9) 35.5 (6.5) p<0.05
Asthma duration (years) 20.6 (1.8) 23.4 (2.6) 18.1 (2.4) NS
Smoker
Current 12 6 6 NS
Ever 13 6 7 NS
Atopy (%) 40 (55%) 21 (62%) 19 (49%) NS
Inhaled steroid at referral (µg BDP equivalent)* 2347 (148) 2941 (206) 1828 (173) p<0.001
Rescue steroid courses in preceding 12 months 4.3 (0.4) 5.3 (0.7) 3.7 (0.4) p<0.05
Maintenance systemic steroid 21 16 5 p<0.01
Hospital admission in preceding 12 months 0.85 (0.2) 1.0 (0.33) 0.7 (0.2) NS
Unscheduled visits in preceding 12 months† 5.3 (1.2) 4.8 (0.9) 5.7 (2.2) NS
Previous specialist attendance 43 26 17 p<0.01
Pre-bronchodilator FEV1 (l) 2.1 (0.10) 1.90 (0.14) 2.27 (0.15) NS
Pre-bronchodilator FEV1% 72 (3) 65 (2) 79 (2) p<0.05
FVC% 83 (5) 74 (5) 91 (7) NS
FEV1/FVC ratio% 69 (2) 65 (2) 72 (2) p<0.05
RV (%) 127 (5) 135 (8) 119 (8) NS
TLC (%) 108 (2) 108 (3) 109 (3) NS
TLCO (%) 92 (2) 90 (4) 95 (3) NS
FEV1=forced expiratory volume in 1 second; FVC=forced vital capacity; RV=residual volume; TLC=total lung capacity; TLCO=carbon monoxide transfer
factor.
*Bioequivalence of inhaled steroids was fluticasone = 2 × beclomethasone = 2 × budesonide.
†Unscheduled visits include visits to primary care and hospital accident and emergency departments.
Data are presented as mean (SE) or absolute values.
Table 2 Clinical, asthma quality of life (QoL), anxiety and depression scores, and blood parameters at presentation in
all subjects and those with therapy resistant asthma (TRA) and non-TRA after evaluation
All patients (n=73) TRA (n=34) Non-TRA (n=39) p value
Upper airway symptoms
(% scoring 0, 1, 2)*
32, 57, 11 32, 47, 21 30, 67, 3 NS
Social problem
(% scoring 0, 1, 2)*
63, 26, 11 65, 32, 3 61, 21, 18 NS
Psychological problem
(% scoring 0, 1, 2)*
53, 32, 15 59, 35, 6 49, 28, 23 NS
Reflux symptoms
(% scoring 0, 1, 2)*
27, 44, 29 24, 44, 32 31, 43, 26 NS
Total clinical score (median, range)* 3 (0–6) 3 (0–5) 3 (0–6) NS
Asthma QoL score (at baseline)† 3.3 (0.14) 3.3 (0.22) 3.2) 0.17) NS
Anxiety score‡ 10.6 (0.6) 10.6 (0.7) 10.7( 0.9) NS
Depression score‡ 7.3 (0.5) 7.3 (0.7) 7.2 (0.9) NS
Total IgE (kU/l) 257 (46) 347 (90) 179( 33) NS
Sputum eosinophils (%) 9 (3) 12 (6) 6 (3) NS
Blood eosinophils (×109/l) 0.41 (0.05) 0.45 (0.06) 0.39 (0.08) NS
*Clinical scores were graded by the assessing physician on the basis of clinical history and graded 0 (not present/no symptoms), 1 (minor factor/minor
symptoms), 2 (major factor/severe symptoms) and presented as % subjects in individual groups.
†Asthma related quality of life was assessed using the Juniper scale.7 The response options for each of the 32 items are on a 7 point scale ranging from 1
(totally limited) to 7 (not at all limited); a clinically minimal significant change in overall score is 0.5.
‡Anxiety and depression scores were measured using the Hospital Anxiety and Depression scale8 (scores categorised as normal 0–7, mild 8–10,
moderate 11–14, severe 15–21).
Data are presented as mean (SE) or absolute values unless stated otherwise.
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attend), although only one of the TRA group refused to attend.
Thirteen (18%) failed to attend for ENT assessment, one from
the TRA group. A 24 hour oesophageal pH profile was not
available in 19 subjects (26%), five of whom were in the TRA
group (eight failed to attend for the procedure, six were
unable to tolerate the probe, one failed recording, and four
refused the test after substantial symptomatic improvement
(non-TRA group)). A high resolution CT scan was not
available in 13 subjects (18%), only one of whom was in the
TRA group (seven refused scan after substantial clinical
improvement and six failed to attend). Sputum eosinophil
counts were available in only 31 of the 73 subjects (42%); the
remainder failed to expectorate an adequate sample or to tol-
erate the induction procedure.
The recorded period of instability was significantly longer in
subjects who subsequently had TRA (table 1). They also
tended to be on a higher dose of inhaled steroid at referral, had
significantly more courses of systemic steroids in the previous
year, and were more likely to be on maintenance systemic
steroids. It is noteworthy that, of the 21 subjects on
maintenance systemic steroids at referral, 11 successfully
withdrew their steroids including five who subsequently did
not have TRA. A further seven subjects who were not on sys-
temic steroids at referral required maintenance systemic ster-
oids, but this group had had a median of six courses of
systemic steroids in the preceding 12 months (range 2–8
courses). Subjects with TRA were more likely to have attended
a respiratory specialist in the past, had lower percentage pre-
dicted FEV1, and were more obstructed at referral (table 1).
No differences were seen in individual or cumulative clini-
cal scores for the individual groups (table 2). There was no
difference in asthma related quality of life or HAD scores
between the groups at baseline (table 2).
Subjects with TRA were less likely to have an additional
diagnosis accounting for a proportion of their symptoms
(table 3). The frequency of additional diagnoses is shown in fig
1. In addition, three subjects had a history consistent with
sulphite sensitivity (two had urticaria after exposure) and
were given a trial exclusion diet. Gastro-oesophageal reflux,
ENT pathology, and psychiatric morbidity were common but
were not more prevalent in either group, although subjects
with TRAwere more likely to have osteoporosis (table 3). After
evaluation and management, subjects with TRA were on
significantly higher doses of inhaled steroids and also had a
significantly lower best FEV1% recorded during the period of
follow up (table 3). At baseline there was no difference in the
asthma related quality of life scores between groups; however,
a significant and clinically relevant increase was seen in those
with therapy responsive asthma but not in the TRA group
(table 3).
Using multivariate logistic regression analysis, the follow-
ing five variables at presentation were identified as being of
potential prognostic significance (using a p value of <0.1):
higher dose of inhaled steroid, previous specialist attendance,
higher total IgE, lower FEV1 % predicted, and a longer recorded
period of instability. These variables were subsequently
dichotomised and the following contrasts considered: inhaled
steroid dose >2000 µg BDP equivalent, previous specialist
referral, total IgE >120 kU/l, FEV1% <70% predicted, and
period of instability >24 months. This did not result in any
loss of fit, as measured by the χ2 test, so dichotomy did not
result in a weaker model. The final model selection was parsi-
monious (table 4, cut off p<0.05) and was used to generate
Table 3 Investigation results and outcome parameters in all subjects and those with therapy resistant asthma (TRA) and
non-TRA after evaluation
All patients (n=73) TRA (n=34) Non-TRA (n=39) p value
Additional diagnosis 25 7 18 p<0.05
ICD10 psychiatric diagnosis* 32/65 (49%) 16/33 (48%) 16/32 (50%) NS
Unrecognised psychiatric illness* 27 (41%) 15 (45%) 12 (38%) NS
ENT examination†
Normal 3 1 2 NS
Mucosal 31 17 14
Structural 26 15 11
Oesophageal reflux‡ 31/54 17/29 14/25 NS
Bone density§
Normal 28 11 17 p<0.05
Osteopenia 21 10 11
Osteoporosis 10 8 2
Lowest dose inhaled steroid (µg BDP equivalent)¶ 1388 (74) 1894 (31) 946 (88) p<0.001
Maintenance steroid after evaluation 17 17 0 p<0.001
Best pre-bronchodilator FEV1% 89 (3) 83 (4) 95 (4) p<0.05
Time to best FEV1 (months) 6.15 (0.7) 6.3 (0.9) 6.0 (1.0) NS
Asthma QoL score at follow up 4.0 (0.19) 3.6 (0.25) 4.4 (0.27) p<0.05
Mean difference from baseline 0.31 1.05
(95% confidence interval) (–0.03 to 0.66) (0.59 to 1.52)
*ICD10 psychiatric diagnoses were assigned after psychiatric interview and included depression, generalised anxiety disorder, panic disorder, specific
phobia, anorexia nervosa, paranoid delusional disorder, bipolar affective disorder, acute stress reaction, post traumatic stress disorder and
obsessive-compulsive personality disorder.
†Structural abnormalities on ENT examination were septal deviation, hypertrophy of middle/inferior turbinates, and nasal polyps.
‡Oesophageal reflux was defined as distal oesophageal pH <4 for >4.7% of total time.9
§Osteoporosis was defined as T score <– 2.5 and osteopenia as –1<T score<– 2.5 on DEXA scan.
¶Lowest dose of inhaled steroid represents the lowest dose of inhaled steroid during the follow up period.
Data are presented as mean (SE) or absolute values.
Figure 1 Additional diagnoses causing respiratory symptoms in 73
sequential referrals to a difficult asthma service (for definitions see
text). Twenty five of the 73 subjects (34%) had an additional
diagnosis.
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estimates of probability of having TRA with different
prognostic combinations at presentation (table 5).
DISCUSSION
This study shows that there is significant co-morbidity in a
population of unselected sequentially referred asthmatics
with persisting refractory symptoms. A systematic evaluation
protocol allows recognition and management of these
co-morbidities and identification of a population of asthmatics
with true therapy resistant disease. However, our initial
hypothesis that patients with TRA would have fewer identifi-
able co-morbidities amenable to treatment was not supported
because we were unable to identify any difference in
co-morbidities (other than osteoporosis) between the groups.
Therapy resistant disease was defined on the basis of clini-
cal assessment and treatment requirements. This differentia-
tion is supported by the asthma quality of life data where
there was no difference at baseline between the groups, but
those defined as having a therapeutic response had signifi-
cantly higher and clinically relevant improvements in their
asthma related quality of life scores after evaluation and
treatment.10 It is also noteworthy that, in the TRA group,
despite systematic and detailed assessment of provoking fac-
tors and meticulous management of their asthma, asthma
quality of life scores did not show any clinically relevant
change. This suggests that, if TRA is present, management of
identified co-morbidity will have little impact on disease spe-
cific quality of life.
Only one previous systematic evaluation protocol for
patients with poorly controlled asthma has been published.11
This protocol evaluated 42 patients over an 8 year period from
1982 to 1990 and concluded that, after working through the
protocol, 74% were no longer difficult to control which
suggests that protocol guided care improves outcome both in
terms of lung function and patient symptoms. In that study
one of the most useful interventions was commencing
patients on inhaled corticosteroids, which reflects asthma
management at the time but also suggests that their subjects
had mild to moderate asthma.
As anticipated, during the protocol there were a number of
failures to attend and pre-agreed withdrawals from psychiat-
ric and ENT assessments, CT chest scans, and oesophageal pH
monitoring, although this was minimal in the therapy resist-
ant group. Because of this, we believe that failure to have these
assessments is unlikely to have reclassified any of the patients
and would not alter the conclusions from this observational
study. The pre-agreed attendance failures reflected a response
to achieving better symptom control and a decision that addi-
tional investigation and assessment was not required. We
believe the unplanned failures to attend for assessments are
also indicative of symptomatic improvement and a decision by
the subject that further evaluation was not required.
There were a number of demographic features present at
referral which could be used to identify subjects with TRA.
Subjects were more likely to record poor asthma control for a
longer period of time compared with subjects whose disease
responded to targeted intervention. They were also more likely
to have been previously assessed by a respiratory specialist,
which suggests a prior period of refractory disease. While we
did not establish if their disease had previously stabilised and
then relapsed or remained unstable, the observations taken
together suggest that the pattern of therapy resistant disease,
once evolved, tends to persist with time.
In addition, patients with TRA had both lower initial FEV1 %
and lower best FEV1 %, consistent with a greater degree of
fixed airflow obstruction and airways remodelling which does
not relate to the presence of previous or current smoking. This
is consistent with previous studies showing significantly
reduced lung function in subjects with severe asthma.12 13 As
our study was cross sectional, it is impossible to determine
whether worse lung function causes TRA or vice versa. Given
the prolonged period of instability and the fact that there was
no difference in the duration of asthma, these observations
suggest that unstable disease (which could be regarded as a
surrogate of uncontrolled or a particular type of therapy
resistant inflammation) is associated with progressive remod-
elling and an accelerated decline in lung function.
Sputum eosinophilia at presentation was not related to the
presence of TRA.We believe that this is because an initial spu-
tum eosinophilia is likely to reflect both subjects with
relatively refractory inflammation and other subjects who are
variably compliant at presentation. A previous cross sectional
study has shown a relationship between sputum eosinophilia
and the degree of fixed airflow obstruction in subjects with
severe asthma.12 There was a trend towards higher eosinophil
counts in subjects with lower post-bronchodilator FEV1%
(data not shown) but this was not significant. The failure of a
large number of subjects to tolerate the sputum induction
procedure or to produce an adequate sample may also be rel-
evant as this may select a subgroup of asthmatics within the
overall group.
Subjects with TRA were taking significantly higher doses of
inhaled steroids at referral than those with non-TRA. The
mean dose in the TRA group was above the maximal
recommended dose for inhaled steroids1 and probably reflects
persisting failure to respond to treatment over time and a
gradual increase in anti-inflammatory medication in an
attempt to gain control. Given that the dose response curve for
inhaled steroids is relatively flat at higher doses with increased
side effects due to systemic bioavailability, it is probable that
some of these subjects were receiving inappropriately high
doses of inhaled steroids.14
Patients with TRA also received more rescue courses of
steroids in the preceding year and were more likely to be on
maintenance systemic steroids at referral, consistent with
more severe and relatively steroid dependent disease. It is
notable, however, that five of 21 (24%) subjects who were on
systemic steroids at referral did not have TRA and strongly
supports early referral of subjects requiring maintenance sys-
temic steroids for specialist assessment.
Table 4 Potential prognostic factors at presentation
for having therapy resistant asthma (TRA) after
variables were dichotomised using logistic regression
analysis
Odds ratio (95% CI)
Inhaled steroid >2000 µg at referral 8.5 (2.2 to 33.1)
Previous specialist attendance 4.4 (1.3 to 15.0)
Pre-bronchodilator FEV1% <70% predicted 4.0 (1.2 to 13.9)
Table 5 Probability of therapy resistant asthma (TRA)
when different prognostic factors were present at
presentation
Inhaled steroid
>2000 µg BDP
equivalent
Presenting FEV1
<70% predicted
Previous
specialist
referral
Probability of
TRA
× × × 0.08
× × U 0.27
× U × 0.29
U × × 0.44
× U U 0.62
U × U 0.76
U U × 0.78
U U U 0.93
U=variable present; ×=variable absent.
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The large doses of inhaled steroids and frequent systemic
steroids are consistent with the observation that osteoporosis
was significantly more prevalent in the TRA group. It is also
consistent with the greater period of instability during which,
based on the 12 month pre-referral period, they probably
would have had further significant exposure to systemic ster-
oids. It is interesting that the duration of asthma did not dif-
fer between the groups, which is consistent with the
suggestion that it is the higher cumulative steroid exposure
that occurs during unstable disease which causes premature
loss of bone density.
As anticipated, identifying a diagnosis in addition to
asthma which contributed to symptoms was associated with
non-TRA. In addition, prior assessment by another respiratory
specialist was associated with TRA, although this did not
appear to be related to identification of an additional diagno-
sis (those with prior specialist assessment included 16 of the
25 subjects assigned an additional diagnosis). There was also
no relationship with any particular individual additional
diagnosis.
The logistic regression analysis defined a number of demo-
graphic variables which appeared to be of prognostic
significance. We believe the three variables in the final model
(inhaled steroid dose >2000 µg, pre-bronchodilator FEV1 of
<70% on this dose of inhaled steroid, and previous respiratory
specialist referral) reflect relative steroid resistance and
chronic unstable disease. It is interesting that a pre-
bronchodilator FEV1 of <70% at presentation despite high
dose inhaled steroids and long acting β2 agonist predicted
resistance to treatment. In the TRA group the pre-
bronchodilator FEV1% at presentation was significantly lower
than the best pre-bronchodilator FEV1% during follow up,
suggesting that it is the inability to maintain lung function at
a certain level despite intensive treatment rather than the
degree of fixed airflow obstruction that defines therapy resist-
ant disease. In support of this, we have shown that the loss of
relationship between objective measures of asthma control
and FEV1% in patients with severe asthma is explained by
patients with fixed airflow obstruction (data not shown). In
this group, fixed airflow limitation presumably generates
exertional symptoms only, but other features of poor asthma
control such as night time symptoms are not problematic.
From table 5 it can be seen that any combination of these
three variables at presentation produces a range of prognostic
probabilities as to whether a patient has TRA. Thus, if a patient
is on >2000 µg inhaled steroid, has a pre-bronchodilator FEV1
of <70% on this dose of inhaled steroids, and has previously
attended a respiratory specialist, the chance of that patient
having TRA is 93%. Similarly, if none of these factors is
present, the chance of having TRA falls to 8%. The final model
is simple and easy to apply and the variables are easily ascer-
tained at presentation. We are currently evaluating this model
prospectively in a separate cohort to determine negative and
positive predictive values.
In summary, we have evaluated in detail a cohort of
sequentially referred patients with difficult to control asthma
and have identified significant co-morbidity in this popula-
tion. Over 50% of those evaluated subsequently did not have
TRA, supporting the use of a detailed and systematic
evaluation of this population. In contrast to our original
hypothesis, we did not identify fewer treatable provoking fac-
tors in the TRA group, but treatment of identified co-
morbidities had no impact on asthma related quality of life in
this group. We have identified a number of demographic fea-
tures at presentation which are associated with the presence
of TRA, and developed a simple model which will define
patients with TRA at presentation.We are currently evaluating
the predictive value of this model in a further cohort of
patients.
. . . . . . . . . . . . . . . . . . . . .
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